Corporate Profile
At 60 Degrees Pharmaceuticals, Inc. (60P) we apply cutting-edge science and research to develop and commercialize new small molecule therapeutics for the prevention and treatment of infectious diseases. Our lead therapeutic, ARAKODA® (tafenoquine), is an FDA-approved malaria-preventative treatment marketed in the U.S. The 60P clinical pipeline includes development programs for treatment of tick-borne (babesiosis), fungal and viral diseases. Our team's top priorities are commercialization of ARAKODA® for malaria prevention and completion of three targeted clinical trials of tafenoquine in babesiosis in support of future application(s) to FDA to expand ARAKODA® labeling.